3652 results for «355»

Filter By

3652 results

From crossroads to crossovers: cracking the left main code

20 May 2025 – From EuroPCR 2025

Navigate complex scenarios in left main coronary artery interventions with this session focusing on protected left main and multivessel disease, IVUS-guided PCI, stent optimization, and in-stent restenosis management. Real-world cases from Azerbaijan, Moldova, and Iraq provide collaborative insights and innovative strategies for challenging coronary anatomy.

From crossroads to crossovers: cracking the left main code

Strategic decision in stent failure

20 May 2025 – From EuroPCR 2025

Explore strategic decision-making in cases of stent failure in this session presenting complex clinical scenarios. Through detailed case analyses, including challenging left main trifurcation lesions and NSTEMI in the presence of chronic total occlusions, discover treatment approaches and key learnings to optimize patient outcomes.

Strategic decision in stent failure

STEMI - What if a culprit lesion is not identifiable?

20 May 2025 – From EuroPCR 2025

Address challenging STEMI cases where culprit lesions are not immediately identifiable. This session emphasizes the utility of intravascular imaging in guiding decision-making and optimizing percutaneous interventions through illustrative cases involving left main stenosis, ambiguous culprit lesions, and etiological dilemmas in coronary occlusion.

STEMI - What if a culprit lesion is not identifiable?

Integrative step-by-step approach to perform successful CTO interventions: from angiographic evaluation to strategy selection

20 May 2025 – From EuroPCR 2025

Master the integrative step-by-step approach to successful chronic total occlusion (CTO) interventions. This session emphasizes systematic angiographic evaluation and strategy selection ranging from simple to complex techniques, supplemented by blinded case discussions for practical learning.

Integrative step-by-step approach to perform successful CTO interventions: from angiographic evaluation to strategy selection

Managing TAVI complications

20 May 2025 – From EuroPCR 2025

Gain expertise in managing TAVI complications including strategic retrieval of embolized valves, handling unexpected additional valve usage, managing left ventricle suicide phenomenon, and integrating coronary intervention tools during structural heart procedures, supported by instructive case series.

Managing TAVI complications

Novelty in no-reflow management in STEMI patients

20 May 2025 – From EuroPCR 2025

Discover novel approaches to manage no-reflow phenomenon in STEMI patients. This session covers innovative therapies including the OPTI-STEMI trial strategies, mechanical thrombectomy, pharmacological interventions with Cangrelor, and super saturated oxygen therapy targeting coronary microcirculation preservation.

Novelty in no-reflow management in STEMI patients

PCI in cardiogenic shock without left ventricular support

20 May 2025 – From EuroPCR 2025

Explore PCI strategies in cardiogenic shock without left ventricular support through challenging cases including STEMI with single patent vessels, balancing procedural and resource considerations, spontaneous coronary dissections with arrhythmia, and use of crush techniques to rescue critically ill patients.

PCI in cardiogenic shock without left ventricular support

Contemporary challenges in acute coronary syndromes

20 May 2025 – From EuroPCR 2025

Examine contemporary challenges in acute coronary syndromes (ACS) through recent trials and studies. Topics include long-term outcomes of deferred stenting, thrombectomy techniques, PCI in cardiogenic shock, and revascularisation strategies, providing a comprehensive update for clinical practice.

Contemporary challenges in acute coronary syndromes

Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

08 Jan 2025

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author

Bruno Scheller
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions

BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial

26 Aug 2023

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Nicola Ryan

Author

Nicola Ryan
BIOFLOW DAPT - Biodegradable polymer SES vs durable polymer ZES in HBR subjects with 1-month DAPT

Top Interventional Trials presented at ACC.21

07 Jun 2021

Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21

Ali Nazmi Calik

Author

Ali Nazmi Calik
Top Interventional Trials presented at ACC.21

Future directions of drug-coated balloon angioplasty

06 Feb 2025

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Dr. F. Alfonso

Author

Fernando Alfonso
Javier Cuesta

Author

Javier Cuesta
Future directions of drug-coated balloon angioplasty
Didn’t find what you were looking for?